Relief For Prostate Cancer Patients Sidelined by Hot Flashes
- Hot flashes remain one of the most prevalent and disruptive adverse effects of androgen deprivation therapy (ADT) in men with prostate cancer, affecting an estimated 60–80% of patients. Despite their frequency and impact on quality of life, treatment options have historically been limited, variably effective, or associated with undesirable side effects.
- New data from the phase II Alliance A222001 trial now provide high-quality evidence supporting oxybutynin as an effective and well-tolerated option for managing ADT-associated hot flashes.
Alliance A222001 was a randomized, double-blind, placebo-controlled phase II trial designed to evaluate whether oral oxybutynin could reduce hot flash frequency and severity in men receiving ADT for prostate cancer. Oxybutynin, an anticholinergic agent widely used for overactive bladder, has previously demonstrated efficacy for hot flash management in women, but prospective randomized data in men receiving ADT were lacking.
Eligible participants were men aged 18 years or older with prostate cancer on a stable regimen of ADT who reported bothersome hot flashes, defined as at least 28 episodes per week.
Patients were randomized to receive:
- oxybutynin 2.5 mg twice daily
- oxybutynin 5 mg twice daily
- or matching placebo for six weeks.
Primary endpoint was change in patient-reported hot flash score from baseline to week six, with secondary endpoints including hot flash frequency, quality-of-life interference, and safety.
Efficacy Outcomes
A total of 88 men were enrolled across 15 academic and community oncology centers in the United States, with 81 eligible for final analysis. At baseline, participants reported an average of 10.1 hot flashes per day and a mean daily hot flash score of 18.2.
Both oxybutynin dose levels demonstrated superior efficacy compared with placebo, with a clear dose-response relationship. Mean reductions in daily hot flash frequency were:
-
2.15 hot flashes/day with placebo
-
4.77 hot flashes/day with oxybutynin 2.5 mg twice daily
-
6.89 hot flashes/day with oxybutynin 5 mg twice daily
Reductions in hot flash severity followed a similar pattern. Mean decreases in daily hot flash scores were 4.85 points with placebo, compared with 9.94 points in the lower-dose oxybutynin arm and 13.95 points in the higher-dose arm.
Improvements were observed early, with symptom reduction beginning within the first week of treatment and reaching maximal effect by week four, which was sustained through the end of the six-week study period.
Clinically meaningful improvement (defined as a ≥50% reduction in hot flash score) was achieved in 32% of patients receiving placebo, compared with 57% of patients in the 2.5 mg oxybutynin group and 79% of those receiving 5 mg twice daily.
Impact on Quality of Life
Beyond frequency and severity, hot flashes can significantly interfere with daily functioning. This trial incorporated the Hot Flash–Related Daily Interference Scale (HFRDIS) to assess patient-reported impact on domains such as sleep, mood, concentration, and overall quality of life.
Patients receiving oxybutynin experienced substantially greater improvements in HFRDIS total scores than those receiving placebo. Mean improvements were:
- Oxybutynin 2.5 mg twice daily: 14.2 points.
- Oxybutynin 5 mg twice daily: 20.7 points.
- Placebo: 3.1 points
The higher-dose oxybutynin group demonstrated statistically significant improvements across multiple domains, including sleep, mood, relationships, enjoyment of life, and overall quality of life.
These findings suggest that oxybutynin not only reduces the physiologic burden of hot flashes but also delivers meaningful functional benefit that may help patients better tolerate long-term ADT.
Safety and Tolerability
Oxybutynin was generally well tolerated in this older prostate cancer population (mean age 68.5 years). No treatment-related grade 3 or higher adverse events were reported. The most common side effect was dry mouth, consistent with oxybutynin’s established anticholinergic profile, and appeared to be dose dependent.
Importantly, concerns specific to men receiving ADT (such as urinary retention and worsening lower urinary tract symptoms) were not substantiated in this trial.
International Prostate Symptom Score (IPSS) measurements showed minimal change across all study arms, and patients receiving oxybutynin did not demonstrate clinically significant worsening of urinary symptoms.
Similarly, patient-reported cognitive effects, including memory or concentration issues, did not worsen significantly over the six-week treatment period. While longer-term cognitive effects were not formally assessed, these short-term findings are reassuring.
Clinical Context and Implications
ADT-associated hot flashes are more than a nuisance symptom; they are linked to sleep disturbance, fatigue, and reduced quality of life, and may contribute to early discontinuation of therapy. Prior pharmacologic options such as megestrol acetate, medroxyprogesterone, and gabapentin are effective for some patients but are not universally tolerated or effective.
The magnitude of benefit observed with oxybutynin in Alliance A222001 compares favorably with previously studied agents, with the added advantage of a well-characterized safety profile and widespread clinical familiarity. The inclusion of two dose levels provides practical guidance, allowing clinicians to balance efficacy and tolerability when selecting a starting dose.
While confirmation in larger phase III studies would be valuable, these data strongly support oxybutynin as a viable and effective supportive care option for men experiencing ADT-associated hot flashes, addressing an unmet need in routine prostate cancer management. One leading prostate cancer specialist, Urologic Oncologist Dr. Leonard G. Gomella from Philadelphia’s Thomas Jefferson University, is embracing the new data with enthusiasm, telling SurvivorNet, “we currently do not have a standard treatment for this annoying condition. The new research just reported has nicely demonstrated that a readily available and well-studied medication, oxybutynin, can provide men with an effective option for hot flush relief.”
